Evidence map›Paper›PMID 28643387›Full record

ArticleMagnetic resonance in medicine2018

Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy.

Lei Tang, Yi Sui, Zheng Zhong, Frederick C Damen, Jian Li, Lin Shen, Yingshi Sun, Xiaohong Joe Zhou

Abstract read
In one paragraph

Article in Magnetic resonance in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. A case report of gastrointestinal stromal tumor of the duodenum.American journal of translational research · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Diffusion MRI of cancer: From low to high b-values.Journal of magnetic resonance imaging : JMRI · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lei TangDepartment of Radiology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
Yi SuiCenter for MR Research, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID 0000-0002-8177-1661
Zheng ZhongCenter for MR Research, University of Illinois at Chicago, Chicago, Illinois, USA.
Frederick C DamenCenter for MR Research, University of Illinois at Chicago, Chicago, Illinois, USA.
Jian LiDepartment of Gastroenterology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
Lin ShenDepartment of Gastroenterology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
Yingshi SunDepartment of Radiology, Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Beijing, China.
Xiaohong Joe ZhouCenter for MR Research, University of Illinois at Chicago, Chicago, Illinois, USA.

Funding

A High-End 3 Tesla Human MRI Scanner Dedicated to ResearchS10RR028898 · NCRR · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ZHOU, XIAOHONG JOE · 2010 to 2010
$2.9M
NCRR NIH HHS S10 RR028898
6 · The paper itself

Abstract

purposeTo demonstrate the clinical value of a non-Gaussian diffusion model using fractional order calculus (FROC) for early prediction of the response of gastrointestinal stromal tumor to second-line sunitinib targeted therapy.

methodsFifteen patients underwent sunitinib treatment after imatinib resistance. Diffusion-weighted imaging with multiple b-values was performed before treatment (baseline) and 2 weeks (for early prediction of response) after initiating sunitinib treatment. Conventional MRI images at 12 weeks were used to determine the good and poor responders according to the modified Choi criteria for MRI. Diffusion coefficient D, fractional order parameter β (which correlates to intravoxel tissue heterogeneity), and a microstructural quantity µ were calculated using the FROC model. The FROC parameters and the longest diameter of the lesion, as well as their changes after 2 weeks of treatment, were compared between the good and poor responders. Additionally, the pretreatment FROC parameters were individually combined with the change in D (ΔD) using a logistic regression model to evaluate response to sunitinib treatment with a receiver operating characteristic analysis.

resultsForty-two good-responding and 32 poor-responding lesions were identified. Significant differences were detected in pretreatment β (0.67 versus 0.74, P = 0.011) and ΔD (45.7% versus 12.4%, P = 0.001) between the two groups. The receiver operating characteristic analysis showed that ΔD had a significantly higher predictive power than the tumor size change (area under the curve: 0.725 versus 0.580; 0.95 confidence interval). When ΔD was combined with pretreatment β, the area under the curve improved to 0.843 with a predictive accuracy of 75.7% (56 of 74).

conclusionsThe non-Gaussian FROC diffusion model showed clinical value in early prediction of gastrointestinal stromal tumor response to second-line sunitinib targeted therapy. The pretreatment FROC parameter β can increase the predictive accuracy when combined with the change in diffusion coefficient during treatment. Magn Reson Med 79:1399-1406, 2018. © 2017 International Society for Magnetic Resonance in Medicine.

Indexed as

Gastrointestinal NeoplasmsGastrointestinal Stromal TumorsAdultAgedAntineoplastic AgentsDiffusion Magnetic Resonance ImagingDrug MonitoringFemaleHumansImage Interpretation, Computer-AssistedMaleMiddle AgedModels, StatisticalSunitinibAntineoplastic AgentsSunitinibdiffusion imagingFROC modelGISTsunitinibtargeted therapy response

Identifiers

PMID28643387
PMCPMC5741547

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.